Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point
This tripeptide is ubiquitous in nature and is produced by every organism from bacteria to plants to animals that derives energy from oxidative phosphorylation and respiration
The randomised, double-blind, placebo-controlled study enrolled 2,339 adults with obesity or overweight and at least one weight-related health condition (such as high blood pressure or heart disease) but without diabetes
Keep in mind, you can get help any time with Healthon
This anesthetic is specifically chosen to minimize the effects on changes in blood pressure and thus provide an ideal perfusion pressure to the kidneys to perform renal function study
